var data={"title":"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/contributors\" class=\"contributor contributor_credentials\">Dennis L Stevens, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Streptococcal toxic shock syndrome (TSS) is a clinical illness characterized by shock and multiorgan failure. Streptococcal TSS consists of isolation of group A <em>Streptococcus </em>(GAS) from a normally sterile body site, together with hypotension, tachycardia, and evidence of organ failure, such as acute respiratory distress syndrome, coagulopathy, liver failure, or renal failure [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. It occurs as a result of capillary leak and tissue damage due to release of inflammatory cytokines induced by streptococcal toxins.</p><p>Streptococcal TSS occurs most frequently in the setting of invasive infection due to group A <em>Streptococcus </em>(<em>Streptococcus pyogenes</em>). GAS typically causes pharyngitis or skin and soft tissue infection; these are generally responsive to appropriate antibiotic therapy, and patients do not develop streptococcal TSS [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Less commonly, GAS causes invasive disease such as necrotizing infection of the skin and fascia, gangrenous myositis, bacteremia, or pneumonia [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/3\" class=\"abstract_t\">3</a>], and these types of infection are complicated by TSS in approximately one-third of cases [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p>The epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome will be reviewed here. The treatment of streptococcal toxic shock syndrome is discussed separately. (See <a href=\"topic.htm?path=treatment-of-streptococcal-toxic-shock-syndrome\" class=\"medical medical_review\">&quot;Treatment of streptococcal toxic shock syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Invasive infections associated with group A streptococcal (GAS) toxic shock syndrome (TSS) have been reported with increasing frequency, predominantly from North America and Europe [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/1,4-13\" class=\"abstract_t\">1,4-13</a>]. There are an estimated 3.5 cases of invasive GAS per 100,000 persons, with a case-fatality rate of 30 to 60 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/3,13-16\" class=\"abstract_t\">3,13-16</a>]. One study noted an increase in the incidence of invasive group A streptococcal disease in Utah between 2002 and 2010, from 3.5 to 9.8 cases per 100,000 [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/17\" class=\"abstract_t\">17</a>]. Up to one-third of patients with invasive GAS disease developed TSS in reported case series [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/15,18\" class=\"abstract_t\">15,18</a>]. The rate of TSS among patients with necrotizing fasciitis is approximately 50 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/3,19\" class=\"abstract_t\">3,19</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GAS TSS occurs among all age groups. Most patients are not immunosuppressed; diabetes and alcoholism are risk factors described in some studies [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/7,20-25\" class=\"abstract_t\">7,20-25</a>]. Among reports of invasive GAS infections associated with bacteremia in the late 1980s, most patients were either &lt;10 or &gt;60 years of age and had underlying diseases, such as cancer, renal failure, leukemia, and severe burns, or were receiving corticosteroids or other immunosuppressive drugs [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/22-24\" class=\"abstract_t\">22-24</a>]. Invasive infection remains highest in patients &gt;50 years of age.</p><p>Subsequently, the frequency of invasive disease and streptococcal TSS has increased among patients 20 to 35 years of age. This likely reflects increased frequency of two presentations of infection: (1) pregnancy-associated GAS infections and (2) deep infection at the site of muscle injury or blunt trauma, in the absence of a clear portal of entry [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26-29\" class=\"abstract_t\">26-29</a>].</p><p>The following factors have been associated with the development of severe GAS infection [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minor trauma, including injuries resulting in hematoma, bruising, or muscle strain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of nonsteroidal antiinflammatory drugs (NSAIDs)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recent surgery (eg, liposuction, hysterectomy, bunionectomy, bone pinning, breast reconstruction [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/30\" class=\"abstract_t\">30</a>], cesarean section [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/31\" class=\"abstract_t\">31</a>])</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral infection (eg, influenza, varicella) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/32\" class=\"abstract_t\">32</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postpartum state (see <a href=\"#H12\" class=\"local\">'Infection associated with pregnancy'</a> below)</p><p/><p>Among children, varicella infection is a risk factor for invasive GAS infection and TSS [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/32-35\" class=\"abstract_t\">32-35</a>]. In Germany, one study including more than 1300 cases of invasive GAS infection noted association with varicella in approximately 1.5 percent of cases; complications included sepsis (43 percent), streptococcal TSS (24 percent), and necrotizing fasciitis (19 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/34\" class=\"abstract_t\">34</a>]. In the United States, introduction of universal varicella vaccination has been associated with a decline in the rate of varicella-associated invasive GAS infection (27 to 2 percent) between the early 1990s and the early 2000s [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/35\" class=\"abstract_t\">35</a>].</p><p>The association between NSAIDs and severe GAS infection may be attributable to NSAID use for relief of pain associated with traumatic injury. In one retrospective study, authors postulated that NSAID use masked presenting symptoms, delaying diagnosis, or served as an independent predisposing factor to more severe streptococcal infection and shock [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. Predisposition to GAS TSS due to NSAIDs could be mediated via inhibition of neutrophil function, suppression of fever, and augmentation of cytokine release [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/36\" class=\"abstract_t\">36</a>].</p><p>GAS infections usually occur sporadically; they are not generally associated with clusters of cases, although outbreaks of severe GAS infections have occurred in nursing homes [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/37,38\" class=\"abstract_t\">37,38</a>] and among hospitalized patients [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H2696717\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Streptococcal toxic shock syndrome (TSS) occurs most frequently in the setting of infection due to group A <em>Streptococcus </em>(GAS; <em>Streptococcus pyogenes</em>). GAS is an aerobic gram-positive coccus that releases exotoxins that act as superantigens; they are capable of activating the immune system by bypassing the usual antigen-mediated immune response sequence, resulting in the release of large quantities of inflammatory cytokines. Virulence factors and other aspects of GAS pathogenesis are discussed separately. (See <a href=\"topic.htm?path=group-a-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">&quot;Group A streptococcus: Virulence factors and pathogenic mechanisms&quot;</a>.)</p><p>Group B, group C, and group G streptococci have also been associated with toxic shock syndrome. (See <a href=\"topic.htm?path=group-b-streptococcal-infections-in-nonpregnant-adults\" class=\"medical medical_review\">&quot;Group B streptococcal infections in nonpregnant adults&quot;</a> and <a href=\"topic.htm?path=group-c-and-group-g-streptococcal-infection\" class=\"medical medical_review\">&quot;Group C and group G streptococcal infection&quot;</a>.)</p><p><em>Streptococcus suis</em> has emerged as a cause of streptococcal toxic shock-like syndrome (STSLS) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/40\" class=\"abstract_t\">40</a>]. Although this pathogen is traditionally associated with bacterial meningitis, a highly pathogenic strain has emerged with the ability to produce massive quantities of proinflammatory cytokines. (See <a href=\"topic.htm?path=epidemiology-of-bacterial-meningitis-in-adults\" class=\"medical medical_review\">&quot;Epidemiology of bacterial meningitis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H2698987\"><span class=\"h2\">Shock</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common portals of entry for group A <em>Streptococcus</em> (GAS) are the skin, vagina, and pharynx. However, no portal of entry is identified in up to 45 percent of patients who develop GAS toxic shock syndrome (TSS) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p>TSS due to GAS typically presents with pain that precedes physical findings of infection [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. At the site of minor trauma (such as a bruise, strained muscle, or sprained ankle), patients may develop deep infection such as necrotizing fasciitis or myonecrosis within 24 to 72 hours, often with no visible break in the skin. The pain typically involves soft tissue of an extremity but may also mimic peritonitis, pelvic inflammatory disease, pneumonia, acute myocardial infarction, cholecystitis, or pericarditis [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4,41-43\" class=\"abstract_t\">4,41-43</a>].</p><p>Clinical signs of soft tissue infection typically consist of localized swelling and erythema followed by ecchymoses and sloughing of skin; progression to necrotizing fasciitis or myositis occurs in 70 to 80 percent of cases [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4,19\" class=\"abstract_t\">4,19</a>]. An influenza-like syndrome characterized by fever, chills, myalgia, nausea, vomiting, and diarrhea occurs in about 20 percent of patients [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/30\" class=\"abstract_t\">30</a>]. A diffuse, scarlatina-like erythema occurs in about 10 percent of cases [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Fever is common; hypothermia may be present in patients with shock. Altered mental status is observed in about half of patients. Patients may be normotensive on presentation but become hypotensive within the subsequent four hours in about half of cases. Shock is due to both capillary leak and vasodilatation. Despite aggressive therapy, the systolic pressure remains depressed after eight hours in 90 percent of patients [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p>A variety of clinical manifestations may be observed in patients without soft tissue findings (about 20 percent of cases). These include endophthalmitis, perihepatitis, peritonitis, infection associated with pregnancy, myocarditis, pneumonia, varicella infection, or overwhelming sepsis [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/42\" class=\"abstract_t\">42</a>]. GAS TSS is a very rare complication of streptococcal pharyngitis in adults but may be more common in children [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Complications of GAS TSS include bacteremia, renal failure, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation, and, rarely, Waterhouse-Friderichsen syndrome [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/45\" class=\"abstract_t\">45</a>]. ARDS occurs in approximately 55 percent of cases, generally after the onset of hypotension [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Renal dysfunction occurs among nearly all patients within 48 to 72 hours. Hypotension, myoglobinuria, and hemoglobinuria (due to toxin-induced hemolysis) can contribute to the development of acute renal failure. Many patients require dialysis for up to three weeks. In patients who survive, the serum creatinine concentration returns to baseline within four to six weeks.</p><p>Initial laboratory studies may demonstrate mild leukocytosis with significant left shift [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. The serum creatinine concentration is frequently elevated and precedes the development of hypotension in 40 to 50 percent of cases [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. Other common findings include hypoalbuminemia, hypocalcemia, positive blood cultures (in approximately 60 percent of cases), and an increase in the serum creatinine kinase concentration, which suggests the presence of necrotizing fasciitis or myositis [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Infection associated with pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GAS infection associated with pregnancy (also referred to as puerperal sepsis or postpartum infection) was first described by Semmelweis in the 1850s and remains an important cause of maternal and infant mortality worldwide [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26,46\" class=\"abstract_t\">26,46</a>]. Approximately 14 percent of GAS postpartum infections are nosocomially acquired [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/16\" class=\"abstract_t\">16</a>]; onset of postpartum infection can also occur in the community after hospital discharge. Nearly 20 percent of cases of GAS infection occur during the third trimester, prior to onset of labor or rupture of membranes [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Patients with puerperal sepsis due to GAS typically present with fever, abdominal pain, and hypotension without tachycardia or leukocytosis. About 220 cases occur annually in the United States, for an overall rate of 6 cases per 100,000 live births [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/47\" class=\"abstract_t\">47</a>]. In 2002, the case fatality rate was about 3.5 percent. Maternal mortality is highest when infection develops within four days of delivery [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26\" class=\"abstract_t\">26</a>] or during the late third trimester [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Issues related to GAS and pregnancy are discussed further separately. (See <a href=\"topic.htm?path=pregnancy-related-group-a-streptococcal-infection\" class=\"medical medical_review\">&quot;Pregnancy-related group A streptococcal infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2703170\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Group A streptococcal (GAS) toxic shock syndrome (TSS) must be considered in any patient presenting from the community in shock in the absence of a clear etiology. Other important findings include a history of recent trauma, severe pain, and fever. The following clinical guideline for diagnosis of GAS TSS has been established by the Working Group on Severe Streptococcal Infections [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Isolation of GAS from a normally sterile site (eg, blood; cerebrospinal, pleural, or peritoneal fluid; tissue biopsy; or surgical wound)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotension (systolic blood pressure &le;90 mmHg in adults or &lt;5<sup>th</sup> percentile for age in children)</p><p/><p>Plus two or more of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Renal dysfunction (in adults, creatinine &ge;2 <span class=\"nowrap\">mg/dL;</span> in children, &ge;2x the upper limit of normal for age; in patients with preexisting renal disease, &ge;2x elevation over baseline)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coagulopathy (eg, thrombocytopenia, disseminated intravascular coagulation)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver dysfunction (eg, transaminases or bilirubin &ge;2x upper limit of normal; in patients with preexisting liver disease, &ge;2x elevation over baseline)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute respiratory distress syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythematous macular rash, may desquamate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Soft tissue necrosis (eg, necrotizing fasciitis, myositis, or gangrene)</p><p/><p>A diagnosis of probable GAS TSS can be made if GAS is isolated from a normally nonsterile site (eg, throat, vagina, skin lesion) but the patient fulfills the other criteria noted above and no other etiology for the illness is identified.</p><p>Recovery of the organism from blood cultures usually takes 8 to 24 hours. Gram stain of involved tissue demonstrating gram-positive cocci in pairs and chains can provide an early diagnostic clue in many cases.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The abrupt onset of shock in a previously healthy individual has a limited number of causes.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Staphylococcal toxic shock syndrome (TSS) &ndash; Staphylococcal TSS should be considered in the setting of menstruating females or in association with recent surgery or localized staphylococcal abscess. The diagnosis is based on clinical presentation (<a href=\"image.htm?imageKey=ID%2F54778\" class=\"graphic graphic_table graphicRef54778 \">table 1</a>). (See <a href=\"topic.htm?path=staphylococcal-toxic-shock-syndrome\" class=\"medical medical_review\">&quot;Staphylococcal toxic shock syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-negative sepsis &ndash; Clinical manifestations of gram-negative sepsis include fever, hypotension, and respiratory failure. In gram-negative sepsis, renal failure develops after hypotension, whereas, in group A streptococcal (GAS) TSS, renal impairment frequently precedes hypotension. The diagnosis of gram-negative sepsis is established by culture. (See <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typhoid fever &ndash; Clinical manifestations of typhoid include fever, relative bradycardia, or pulse-temperature dissociation and abdominal pain. In typhoid fever, the white blood count is usually normal or low; in GAS TSS, it is generally normal or elevated with a marked left shift. The diagnosis of typhoid fever is established by culture. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rocky Mountain spotted fever (RMSF) &ndash; Clinical manifestations of RMSF include fever, headache, and rash; in GAS TSS, headache is rare and rash is present in only 10 percent of patients. In RMSF, the rash is most often petechial, whereas, in GAS TSS, the rash is diffusely erythematous. The diagnosis of RMSF is based on clinical symptoms. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rocky-mountain-spotted-fever\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Rocky Mountain spotted fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningococcemia &ndash; Clinical manifestations of meningococcemia include fever, nausea, vomiting, headache, and petechial rash. Symptoms of meningitis in GAS TSS are infrequent. The diagnosis of meningococcemia is established by culture. (See <a href=\"topic.htm?path=clinical-manifestations-of-meningococcal-infection\" class=\"medical medical_review\">&quot;Clinical manifestations of meningococcal infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Streptococcus pneumoniae</em> infection &ndash; Clinical manifestations of <em>S. pneumoniae</em> infection include respiratory symptoms and development of lobar consolidation and empyema; these can also occur in the setting of GAS TSS. The diagnosis of <em>S. pneumoniae</em> infection is established via culture. (See <a href=\"topic.htm?path=invasive-pneumococcal-streptococcus-pneumoniae-infections-and-bacteremia\" class=\"medical medical_review\">&quot;Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leptospirosis &ndash; Clinical manifestations of leptospirosis include fever, rigors, myalgia, headache, and abdominal symptoms. Conjunctival suffusion is one of the most reliable distinguishing features of leptospirosis since it rarely occurs with any other infectious illness. The diagnosis of leptospirosis is established via serologic testing. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heat stroke &ndash; Clinical manifestations of heat stroke include core body temperature in excess of 40&deg;C with associated central nervous system dysfunction. Additional manifestations that may also be observed in the setting of GAS TSS include dehydration with evidence of renal impairment, hypotension, and sunburn-type erythema. The history of heat exposure is helpful in distinguishing the two illnesses. (See <a href=\"topic.htm?path=severe-nonexertional-hyperthermia-classic-heat-stroke-in-adults\" class=\"medical medical_review\">&quot;Severe nonexertional hyperthermia (classic heat stroke) in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H92214461\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Skin and soft tissue infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Streptococcal toxic shock syndrome (TSS) is a clinical illness characterized by shock and multiorgan failure; it occurs as a result of capillary leak and tissue damage due to release of inflammatory cytokines induced by streptococcal toxins. Streptococcal TSS occurs most frequently in the setting of infection due to group A <em>Streptococcus </em>(GAS). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are an estimated 3.5 cases of streptococcal TSS per 100,000 persons, with a case-fatality rate of 30 to 60 percent. GAS TSS occurs among all age groups; most patients are not immunosuppressed. Risk factors associated with development of severe GAS infection include minor trauma, use of nonsteroidal antiinflammatory drugs, recent surgery, viral infection, and postpartum state. (See <a href=\"#H8\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxic shock syndrome due to GAS typically presents with pain that precedes physical findings of infection. At the site of minor trauma (such as a bruise, strained muscle, or sprained ankle), patients may develop deep infection such as necrotizing fasciitis or myonecrosis within 24 to 72 hours, often with no visible break in the skin. (See <a href=\"#H8\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>GAS infection associated with pregnancy is an important cause of maternal and infant mortality. Patients with GAS puerperal sepsis typically present with fever, abdominal pain, and hypotension without tachycardia or leukocytosis. Maternal mortality is highest when infection develops within four days of delivery. (See <a href=\"#H12\" class=\"local\">'Infection associated with pregnancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of streptococcal TSS consists of hypotension and isolation of streptococci from a normally sterile site, together with two or more findings including renal dysfunction, coagulopathy liver dysfunction, acute respiratory distress syndrome, rash, <span class=\"nowrap\">and/or</span> soft tissue necrosis. Gram stain of involved tissue demonstrating gram-positive cocci in pairs and chains can provide an early diagnostic clue in many cases. (See <a href=\"#H2703170\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of streptococcal TSS includes staphylococcal TSS, typhoid fever, Rocky Mountain spotted fever, meningococcemia, <em>Streptococcus pneumoniae</em> infection, leptospirosis, and heat stroke. (See <a href=\"#H15\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/1\" class=\"nounderline abstract_t\">Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269:390.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/2\" class=\"nounderline abstract_t\">Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/3\" class=\"nounderline abstract_t\">Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007; 45:450.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/4\" class=\"nounderline abstract_t\">Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/5\" class=\"nounderline abstract_t\">Group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989; 321:1545.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/6\" class=\"nounderline abstract_t\">Martin PR, H&oslash;iby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22:421.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/7\" class=\"nounderline abstract_t\">Wheeler MC, Roe MH, Kaplan EL, et al. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA 1991; 266:533.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/8\" class=\"nounderline abstract_t\">Bartter T, Dascal A, Carroll K, Curley FJ. 'Toxic strep syndrome'. A manifestation of group A streptococcal infection. Arch Intern Med 1988; 148:1421.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/9\" class=\"nounderline abstract_t\">Hr&iacute;balov&aacute; V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988; 108:772.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/10\" class=\"nounderline abstract_t\">Greenberg RN, Willoughby BG, Kennedy DJ, et al. Hypocalcemia and &quot;toxic&quot; syndrome associated with streptococcal fasciitis. South Med J 1983; 76:916.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/11\" class=\"nounderline abstract_t\">Thomas JC, Carr SJ, Fujioka K, Waterman SH. Community-acquired group A streptococcal deaths in Los Angeles County. J Infect Dis 1989; 160:1086.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/12\" class=\"nounderline abstract_t\">Stevens DL. The toxic shock syndromes. Infect Dis Clin North Am 1996; 10:727.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/13\" class=\"nounderline abstract_t\">Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol 2011; 49:4094.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/14\" class=\"nounderline abstract_t\">Nelson GE, Pondo T, Toews KA, et al. Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012. Clin Infect Dis 2016; 63:478.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/15\" class=\"nounderline abstract_t\">Ekelund K, Skinh&oslash;j P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol 2005; 43:1789.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/16\" class=\"nounderline abstract_t\">O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35:268.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/17\" class=\"nounderline abstract_t\">Stockmann C, Ampofo K, Hersh AL, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002-2010. Clin Infect Dis 2012; 55:479.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/18\" class=\"nounderline abstract_t\">Svensson N, Oberg S, Henriques B, et al. Invasive group A streptococcal infections in Sweden in 1994 and 1995: epidemiology and clinical spectrum. Scand J Infect Dis 2000; 32:609.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/19\" class=\"nounderline abstract_t\">Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103:18.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/20\" class=\"nounderline abstract_t\">Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/21\" class=\"nounderline abstract_t\">Stegmayr B, Bj&ouml;rck S, Holm S, et al. Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 1992; 24:589.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/22\" class=\"nounderline abstract_t\">Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge--a review of 67 episodes. Q J Med 1988; 68:603.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/23\" class=\"nounderline abstract_t\">Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect 1989; 18:231.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/24\" class=\"nounderline abstract_t\">Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991; 13:8.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/25\" class=\"nounderline abstract_t\">Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/26\" class=\"nounderline abstract_t\">Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis 2013; 57:870.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/27\" class=\"nounderline abstract_t\">Smit MA, Nyquist AC, Todd JK. Infectious shock and toxic shock syndrome diagnoses in hospitals, Colorado, USA. Emerg Infect Dis 2013; 19:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/28\" class=\"nounderline abstract_t\">Hellstr&ouml;m P. Urinary and sexual dysfunction after rectosigmoid surgery. Ann Chir Gynaecol 1988; 77:51.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/29\" class=\"nounderline abstract_t\">Wasserzug O, Valinsky L, Klement E, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009; 48:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/30\" class=\"nounderline abstract_t\">Agerson AN, Wilkins EG. Streptococcal toxic shock syndrome after breast reconstruction. Ann Plast Surg 2005; 54:553.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/31\" class=\"nounderline abstract_t\">Okumura K, Schroff R, Campbell R, et al. Group A streptococcal puerperal sepsis with retroperitoneal involvement developing in a late postpartum woman: case report. Am Surg 2004; 70:730.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/32\" class=\"nounderline abstract_t\">Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000; 105:E60.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/33\" class=\"nounderline abstract_t\">Zachariadou L, Stathi A, Tassios PT, et al. Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections. Epidemiol Infect 2014; 142:512.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/34\" class=\"nounderline abstract_t\">Im&ouml;hl M, van der Linden M, Reinert RR, Ritter K. Invasive group A streptococcal disease and association with varicella in Germany, 1996-2009. FEMS Immunol Med Microbiol 2011; 62:101.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/35\" class=\"nounderline abstract_t\">Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr 2004; 144:68.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/36\" class=\"nounderline abstract_t\">Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977.</a></li><li class=\"breakAll\">Auerbach SB, Schwartz B, Facklam RR, et al. Outbreak of invasive group A streptococcal (GAS) disease in a nursing home (abstract). In: ICAAC, Atlanta, GA 1990.</li><li class=\"breakAll\">Hohenboken JJ, Anderson F, Kaplan EL. Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality (abstract). In: ICAAC, Atlanta, GA 1994.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/39\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Nosocomial group A streptococcal infections associated with asymptomatic health-care workers--Maryland and California, 1997. MMWR Morb Mortal Wkly Rep 1999; 48:163.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/40\" class=\"nounderline abstract_t\">Ye C, Zheng H, Zhang J, et al. Clinical, experimental, and genomic differences between intermediately pathogenic, highly pathogenic, and epidemic Streptococcus suis. J Infect Dis 2009; 199:97.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/41\" class=\"nounderline abstract_t\">Kanetake K, Hayashi M, Hino A, et al. Primary peritonitis associated with streptococcal toxic shock-like syndrome: report of a case. Surg Today 2004; 34:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/42\" class=\"nounderline abstract_t\">Hung TY, Wang LY, Chen CT, Chen TJ. Streptococcal toxic shock syndrome with initial manifestation of abdominal pain and cholecystitis. Acta Paediatr Taiwan 2005; 46:106.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/43\" class=\"nounderline abstract_t\">Khateeb OM, Osborne D, Mulla ZD. Gastrointestinal symptomatology as a predictor of severe outcomes of invasive group A streptococcal infections. Epidemiol Infect 2010; 138:534.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/44\" class=\"nounderline abstract_t\">Chiang MC, Jaing TH, Wu CT, et al. Streptococcal toxic shock syndrome in children without skin and soft tissue infection: report of four cases. Acta Paediatr 2005; 94:763.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/45\" class=\"nounderline abstract_t\">Karakousis PC, Page KR, Varello MA, et al. Waterhouse-Friderichsen syndrome after infection with group A streptococcus. Mayo Clin Proc 2001; 76:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/46\" class=\"nounderline abstract_t\">Gourlay M, Gutierrez C, Chong A, Robertson R. Group A streptococcal sepsis and ovarian vein thrombosis after an uncomplicated vaginal delivery. J Am Board Fam Pract 2001; 14:375.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-streptococcal-toxic-shock-syndrome/abstract/47\" class=\"nounderline abstract_t\">Chuang I, Van Beneden C, Beall B, Schuchat A. Population-based surveillance for postpartum invasive group a streptococcus infections, 1995-2000. Clin Infect Dis 2002; 35:665.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3162 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">EPIDEMIOLOGY</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Risk factors</a></li></ul></li><li><a href=\"#H2696717\" id=\"outline-link-H2696717\">MICROBIOLOGY</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H2698987\" id=\"outline-link-H2698987\">Shock</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Infection associated with pregnancy</a></li></ul></li><li><a href=\"#H2703170\" id=\"outline-link-H2703170\">DIAGNOSIS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H92214461\" id=\"outline-link-H92214461\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3162|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/54778\" class=\"graphic graphic_table\">- Clinical criteria for staphylococcal toxic shock syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rocky-mountain-spotted-fever\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Rocky Mountain spotted fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-meningococcal-infection\" class=\"medical medical_review\">Clinical manifestations of meningococcal infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-bacterial-meningitis-in-adults\" class=\"medical medical_review\">Epidemiology of bacterial meningitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults\" class=\"medical medical_review\">Gram-negative bacillary bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-a-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">Group A streptococcus: Virulence factors and pathogenic mechanisms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-infections-in-nonpregnant-adults\" class=\"medical medical_review\">Group B streptococcal infections in nonpregnant adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-c-and-group-g-streptococcal-infection\" class=\"medical medical_review\">Group C and group G streptococcal infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-pneumococcal-streptococcus-pneumoniae-infections-and-bacteremia\" class=\"medical medical_review\">Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pregnancy-related-group-a-streptococcal-infection\" class=\"medical medical_review\">Pregnancy-related group A streptococcal infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=severe-nonexertional-hyperthermia-classic-heat-stroke-in-adults\" class=\"medical medical_review\">Severe nonexertional hyperthermia (classic heat stroke) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">Society guideline links: Skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcal-toxic-shock-syndrome\" class=\"medical medical_review\">Staphylococcal toxic shock syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-streptococcal-toxic-shock-syndrome\" class=\"medical medical_review\">Treatment of streptococcal toxic shock syndrome</a></li></ul></div></div>","javascript":null}